GSE64771
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer
We perform RNA-seq on matched orthotopic murine primary and metastatic prostate cancer samples to identify differential gene expressions Overall design: RNA-seq was performed on orthotopic murine primary and metastatic tumor samples using Illumina Hi-Seq 2000 platform